ClinicalTrials.gg
DrugBiological

Pegunigalsidase alfa clinical trials

Also written PRX-102.

studies test it
10
open now
2
in phase 3
8
first study started
2012

How each study uses pegunigalsidase alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the pegunigalsidase alfa studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
9 May 2023 · ELFABRIO · BLA 761161 (FDA, Drugs@FDA)
European Union
4 May 2023 · Elfabrio · EMEA/H/C/005618 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

pegunigalsidase alfa
9
Recombinant human alpha galactosidase-A
7
PRX-102 (pegunigalsidase alfa)
3

Development codes

PRX-102
5

Studies by the year they started

10 studies that test it; most in 2017 (3)

Studies that test pegunigalsidase alfa, by start year
YearStudies
20121
20141
20161
20173
20182
20231
20251

By phase

A phase 1/2 study counts in both.

Phase 1
2
Phase 2
4
Phase 3
8

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 10 · Other 0

Protalix (6) · Chiesi Farmaceutici S.p.A. (4)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1, 1 in phase 3

Studies that test pegunigalsidase alfa, phase 3 first.

Studies

Open first, then newest update. How each study uses pegunigalsidase alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 10

Codes

What other systems call pegunigalsidase alfa · ClinicalTrials.gg INT002167

  • MeSH (NLM) C000731937pegunigalsidase alfaOne source NLM
  • UNII (FDA) 8M7V7Q6537PEGUNIGALSIDASE ALFAConfirmed FDA, NLM
  • NCI Thesaurus C175187Pegunigalsidase AlfaOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.